New Treatment for Prostate Cancer Uses Low-Temperature Plasma
Researchers at the University of York in the UK revealed a new concept in the fight against early-stage prostate cancer in the British Journal of Cancer. Current treatments may be inadequately useful for long-term prognosis and sought to find a viable solution.
Through their trials, the team found the use of low-temperature plasmas caused a type of cell death in the cancerous cells that was different from the types of cell death caused by cryotherapy and radiotherapy. Current treatments may cause apoptosis to which cells can eventually develop a resistance. Plasma therapy causes necrosis (cell death via ruptured membranes).
The study cites success in killing organ-confined prostate cancer cells at a lower cost and higher efficiency rate than traditional radiotherapy and photodynamic therapy. The research team is attempting to test its theories and treatment on three-dimensional tumor replicas to assess precision of plasma treatment in order to better develop the method into a clinically sound treatment.
According to the American Cancer Society, approximately one in seven men in the U.S. will be diagnosed with prostate cancer during their lifetime. An estimated 220,800 new cases of prostate cancer will be diagnosed in 2015 alone, and it is the second most common cancer in American men.
Prostate cancer is one of several cancers that can lead to disabling conditions such as fatigue and chronic pain. If you have been diagnosed with prostate cancer and are undergoing treatment, you may be eligible for Social Security disability benefits if you cannot work. To get started on filing your disability claim, call Disability Help Group at 1-(800)-800-3332.